Clinical Trials Logo

Sickle Cell Disease clinical trials

View clinical trials related to Sickle Cell Disease.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05775224 Enrolling by invitation - Multiple Myeloma Clinical Trials

ASH Research Collaborative Data Hub

Start date: April 29, 2020
Phase:
Study type: Observational [Patient Registry]

Benign and malignant hematologic diseases are relatively rare conditions within the spectrum of medical practice in any one site of care. Nonetheless, recent research in hematologic conditions from basic, translational, clinical and population perspectives offer the possibility of improving the way that these diseases are treated, and the outcomes experienced by patients. A repository that aggregates and validates this data across institutions and other practice settings is needed in order to identify variation in care, new findings, and further research.

NCT ID: NCT05632354 Enrolling by invitation - Sickle Cell Disease Clinical Trials

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Start date: January 5, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease

NCT ID: NCT04628585 Enrolling by invitation - Sickle Cell Disease Clinical Trials

Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy

Start date: October 21, 2020
Phase:
Study type: Observational

This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in the study.

NCT ID: NCT04264871 Enrolling by invitation - Sickle Cell Disease Clinical Trials

Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications

Start date: January 1, 2020
Phase:
Study type: Observational

Children with sickle cell disease systematically receive a transfusion 2 to 5 days before scheduled surgery (with the exception of minor surgeries) in order to avoid post-operative complications of which the vaso-occlusive crisis and acute thoracic syndrome are the most frequent. This standardized preoperative protocol was established on the basis of the results of large-scale randomized studies, most of which date back over ten years, and which have demonstrated the beneficial effects of transfusion (or transfusion exchange) preoperatively. To date, several other more recent studies (but not controlled) have questioned this type of systematic management. The purpose of this study is to review retrospectively data of sickle cell children who have undergone elective surgery at the Huderf in the last ten years and to identify the eventual complications encountered. The most common procedures in these patients are: tonsillectomy with or without associated adenoids, splenectomy and cholecystectomy. General data on sickle cell disease (history, genotype, G6PD deficiency, biology and previous complications), pre-surgical preparation, surgery and post surgical management and complications will be collected and analyzed. This retrospective analysis will allow an objective assessment of the current quality of care and will provide useful data to improve patient management.

NCT ID: NCT04208529 Enrolling by invitation - Sickle Cell Disease Clinical Trials

A Long-term Follow-up Study in Participants Who Received CTX001

Start date: January 20, 2021
Phase: Phase 3
Study type: Interventional

This is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX001 in parent studies 111 (NCT03655678) 141 (NCT05356195) or 161 (NCT05477563) (transfusion-dependent β-thalassemia [TDT] studies) or Study 121 (NCT03745287) or 151 (NCT05329649), 161(NCT05477563),171 (NCT05951205) (severe sickle cell disease [SCD] studies).

NCT ID: NCT02619734 Enrolling by invitation - Sickle Cell Disease Clinical Trials

Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow stem cell implantation for the treatment of leg ulcer in adult patients with sickle cell disease.